Latest Headlines

Latest Headlines

Sanofi and med tech giant Medtronic join forces on diabetes

Sanofi has formed an alliance with medical device titan Medtronic to develop combo therapies that can improve patient adherence and simplify insulin treatment for the world's roughly 350 million sufferers of Type 2 diabetes.

UPDATED: With early data looming, Celgene grabs rights to Agios' leukemia drug

Not long after Agios was established, Celgene leaned in early to grab options on the preclinical cancer drug programs in the biotech's pipeline, paying $130 million upfront to land the deal and extending their option arrangement last year with another $20 million offering. This morning, with Phase I data on a lead program due for public review this weekend, Celgene pounced, agreeing to exercise its option and provide a package of milestones worth up to $120 million to obtain the rights on AG-221.

J&J teams with Glaxo's ViiV on an HIV combo treatment

Johnson & Johnson has signed a deal with ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, to spin their two antivirals into a single tablet, potentially sparing patients from some harsh side effects associated with current therapies and challenging Gilead Sciences' dominance in the field.

J&J helps bankroll a $55M gamble on partner Aduro's PhIIb cancer drug study

With the ink still drying on a $365 million deal to in-license rights to a therapeutic cancer vaccine and immunotherapy tech at Aduro BioTech, J&J is back with the news that it is also helping to bankroll the company's research work, jumping into a syndicate which has pledged $55 million to fuel an advanced drug study.

AstraZeneca extends global shopping spree with $232M asthma drug deal

AstraZeneca's executive crew extended one of the biggest shopping sprees in the industry with a pact, in-licensing rights to a drug from Synairgen that targets the viral infections that afflict the respiratory tracts of asthma patients. And the little biotech's shares soared on the news.

AbbVie to co-promote hep C diagnostic

AbbVie will have exclusive promotion rights to the sole FDA-approved point-of-care test for the hepatitis C virus, under a co-promotion agreement with OraSure Technologies, maker of the OraQuick HCV Rapid Test.

CROs unite to kick-start a biotech's pipeline

Four pharma service providers, led by MPI Research, have joined forces to form KPI Therapeutics, a new biotech designed to develop promising drug candidates and speed their way to market.

InVentiv signs on to market 3-D printed drugs

Aprecia has an MIT-licensed method of 3-D printing pills and a plan to hit the market with easy-to-take formulations of top-selling medicines. To get there, the biotech has tapped CRO inVentiv Health, which is on hand to lend its commercialization expertise.

Bristol-Myers deepens its ties to Biocon's CRO and Indian R&D

As many drugmakers scale down their R&D presences in India, Bristol-Myers Squibb is strengthening its relationship with Syngene, the CRO arm of local giant Biocon.

London's Institute of Cancer Research to help develop MRI-guided radiation systems

The Institute of Cancer Research, London, became the latest member of a consortium seeking to integrate magnetic resonance imaging into radiation therapy.